

THE GLOBAL INFLUENZA MARKET



PHM049C
November 2013

Melissa Elder
Project Analyst

ISBN: 1-56965-628-2

bcc | Research
Market Forecasting

BCC Research
49 Walnut Park, Building 2
Wellesley, MA 02481
866-285-7215, 781-489-7301
www.bccresearch.com
Custom Reports:
carol.laverty@bccresearch.com

TABLE OF CONTENTS

TOPIC	PAGE NO.
CHAPTER 1 INTRODUCTION	2
STUDY GOALS AND OBJECTIVES	2
REASONS FOR DOING THE STUDY	2
SCOPE OF REPORT	2
METHODOLOGY AND INFORMATION SOURCES	2
INTENDED AUDIENCE	3
RELATED BCC RESEARCH STUDIES	3
ANALYST CREDENTIALS	3
BCC RESEARCH ON-LINE SERVICES	4
DISCLAIMER	4
CHAPTER 2 SUMMARY	6
THE INFLUENZA MARKET: MAJOR MARKETS SUMMARY	6
<i>SUMMARY TABLE GLOBAL INFLUENZA MARKET ANALYSIS BY PRODUCT SEGMENT, THROUGH 2018 (\$ MILLIONS)</i>	7
<i>SUMMARY FIGURE GLOBAL INFLUENZA MARKET ANALYSIS BY PRODUCT SEGMENT, 2007-2018 (\$ MILLIONS)</i>	7
CHAPTER 3 INDUSTRY OVERVIEW	9
OVERVIEW	9
HISTORY OF THE MARKET	9
EPIDEMICS/PANDEMICS	9
Spanish Influenza 1918-1919	9
Hong Kong Influenza 1968	10
Asian Influenza 1957	10
Swine Flu 1976	10
Russian Influenza 1977	10
Avian Flu 1961, 1997, 2003-2009/2010 (Sporadic)	10
Novel Influenza H1N1 2009	11
<i>TABLE 1 DISTRIBUTION OF FATAL CASES OF 2009-2010 H1N1 PANDEMIC BY WHO REGION</i>	11
Novel Influenza H7N9	12
<i>TABLE 2 CUMULATIVE NUMBER OF CONFIRMED CASES AND DEATHS OF H7N9 BY MONTH, AS OF AUGUST 2013</i>	12
<i>TABLE 3 NUMBER OF CONFIRMED CASES OF H7N9 BY REGION, AS OF AUGUST 2013</i>	12
VIRUS MUTATIONS	13
TYPES OF INFLUENZA	13
Influenza Type A	13
Influenza A H5	14
Influenza A H7	14
Influenza A H9	14
Influenza A H1	14
Influenza A H10	14
Influenza Type B	14
Influenza Type C	14

TOPIC	PAGE NO.
WORLD ACTIVITY OF INFLUENZA VIRUSES	14
TABLE 4 WORLDWIDE INFLUENZA ACTIVITY, COUNTRIES AFFECTED BY TYPE	15
THE WORLD HEALTH ORGANIZATION (WHO) AND THE CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC): INFLUENZA RESPONSE	17
WORLD HEALTH ORGANIZATION	17
CENTERS FOR DISEASE CONTROL AND PREVENTION	18
U.S. VIRAL SURVEILLANCE	19
TABLE 5 VIRAL SURVEILLANCE, PERCENT OF INFLUENZA VIRUS TYPE, 2005-2011 FLU SEASONS (%)	19
FIGURE 1 VIRAL SURVEILLANCE TREND FOR INFLUENZA VIRUS TYPE, 2005-2011 FLU SEASONS (%)	19
FDA'S VACCINE AND RELATED BIOLOGICAL PRODUCTS ADVISORY COMMITTEE AND VACCINE COMPOSITION	20
TABLE 6 INFLUENZA VIRUS RECOMMENDATIONS, U.S. INFLUENZA SEASONS, 2003-2014	20
VACCINE RECOMMENDATIONS	21
TABLE 7 THIMEROSAL CONTENT OF INFLUENZA VACCINES (U.S. MANUFACTURED)	22
TABLE 8 CDC INFLUENZA VACCINE RECOMMENDATIONS	23
FIGURE 2 RECOMMENDATIONS REGARDING INFLUENZA VACCINATION OF PERSONS WHO REPORT ALLERGY TO EGGS: ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES, U.S., 2013-2014 INFLUENZA SEASON	24
UNIVERSAL VACCINE	24
POPULATION DEMOGRAPHICS AND INFLUENZA INCIDENCE/MORTALITY	25
GLOBAL DEMOGRAPHICS	25
TABLE 9 GLOBAL POPULATION AND ANNUAL GROWTH BY SELECTED AGE GROUP AND SELECTED YEARS, THROUGH 2030 (MILLIONS)	26
FIGURE 3 GLOBAL POPULATION BY SELECTED AGE GROUP AND SELECTED YEARS, 2000-2030 (MILLIONS)	26
TABLE 10 GLOBAL POPULATION BY SELECTED COUNTRY, THROUGH 2015 (MILLIONS)	27
FIGURE 4 GLOBAL POPULATION BY SELECTED COUNTRY, 2010 AND PROJECTED 2015 (MILLIONS)	28
GLOBAL LIFE EXPECTANCY	28
TABLE 11 GLOBAL LIFE EXPECTANCY AT BIRTH BY SELECTED COUNTRY, 1980 AND 2010 (YEARS)	29
FIGURE 5 GLOBAL LIFE EXPECTANCY AT BIRTH BY SELECTED COUNTRY, 1980 AND 2010 (YEARS)	29
INFLUENZA INCIDENCE AND MORTALITY	30
TABLE 12 WORLDWIDE INFLUENZA STATISTICS, ESTIMATED ON 2012 DATA AND POPULATION	30
TABLE 13 U.S. VIRAL STATISTICS ESTIMATED ON 2012 DATA AND POPULATION	30
TABLE 14 IMPACT OF 2009 H1N1 FLU, CASES AND RELATED HOSPITALIZATIONS AND DEATHS BY AGE GROUP APRIL 2009-APRIL 2010	31
CHAPTER 4 ISSUES AFFECTING THE MARKET	34
H1N1 OUTBREAK 2009 (SWINE FLU)	34
RAPID DIAGNOSTICS	34
Pandemic Testing	34
Seasonal Influenza Tests	35
AVIAN FLU	35

TOPIC	PAGE NO.
U.S. GOVERNMENT INTERVENTION	35
<i>TABLE 15 COUNTRIES/REGIONS AFFECTED BY CURRENT CDC AND USDA BIRD IMPORT RESTRICTIONS</i>	36
AVIAN FLU SURVEILLANCE	36
<i>TABLE 16 WHO-REPORTED CASES OF AVIAN INFLUENZA A/(H5N1) IN HUMANS (NUMBER)</i>	37
<i>FIGURE 6 WHO-REPORTED CASES OF AVIAN INFLUENZA A/(H5N1) IN HUMANS (NUMBER)</i>	38
Avian Flu (H5N1) Outbreaks in Animals	38
<i>TABLE 17 CONFIRMED CASES OF AVIAN FLU OUTBREAKS IN ANIMALS WORLDWIDE, 2003 TO AUGUST 19, 2013 (NUMBER)</i>	39
<i>FIGURE 7 CONFIRMED CASES OF AVIAN FLU OUTBREAKS IN ANIMALS WORLDWIDE, BY REGION, 2003 TO AUGUST 19, 2013 (NUMBER)</i>	40
The WHO and Containment for Pandemic Influenza	41
<i>TABLE 18 APPROVED WHO INFLUENZA CENTERS BY REGION</i>	42
<i>FIGURE 8 NUMBER OF APPROVED WHO INFLUENZA CENTERS BY WHO BROAD REGION (%)</i>	62
INTERNATIONAL INFLUENZA VACCINE STOCKPILE ORDERS	63
PRE-PANDEMIC VACCINATION	64
<i>TABLE 19 TARGETED PRE-PANDEMIC INFLUENZA VACCINE STOCKPILES, BASED ON POPULATION DEMANDS OF SELECTED COUNTRIES (MILLIONS)</i>	64
Biomedical Advanced Research and Development Authority (BARDA)	64
ANTIVIRAL RESISTANCE	65
RECREATED VIRUSES	66
HHS CONTRACTS FOR RELATED TECHNOLOGIES	66
<i>TABLE 20 HHS CONTRACTS AWARDED FOR RESEARCH AND DEVELOPMENT OF RECOMBINANT INFLUENZA VACCINE</i>	67
MARKET FAILURE TO MATERIALIZE	67
MEDIA COVERAGE AND VACCINATIONS	68
EPIDEMIC/PANDEMIC THREAT	68
<i>TABLE 21 ESTIMATED INCIDENCE OF PANDEMIC INFLUENZA FOR 2013 SEVERE OUTBREAKS BASED ON POPULATION ESTIMATES, U.S. CENSUS BUREAU INTERNATIONAL DATABASE SELECTED COUNTRIES (THOUSANDS)</i>	69
PANDEMIC PREPAREDNESS PLANS	71
<i>TABLE 22 ESSENTIAL AND DESIRABLE ELEMENTS OF THE WHO INFLUENZA PANDEMIC PREPAREDNESS PLAN</i>	71
THE UNITED STATES	72
JAPAN	73
<i>TABLE 23 OUTLINE OF JAPAN'S GOVERNMENT ACTION PLAN FOR INFLUENZA PANDEMIC PREPAREDNESS</i>	74
CHINA	75
<i>TABLE 24 CHINA INFLUENZA PANDEMIC WARNING LEVELS</i>	76
BRAZIL	76
<i>TABLE 25 BRAZIL INFLUENZA PANDEMIC WARNING LEVELS AND ACTION</i>	76
UNITED KINGDOM	77
WORLD INFLUENZA IMPACT	78
IMPACT OF SEASONAL FLU ON THE U.S. ECONOMY	78
<i>TABLE 26 NATIONWIDE INFLUENZA-RELATED COSTS AND DISTRIBUTIONS BY AGE GROUP, BY RISK AND BY HEALTH OUTCOME, ALL ADOPTED FROM MOLINARI ET AL., 2007</i>	78

TOPIC	PAGE NO.
HOSPITAL BED UTILIZATION DURING INFLUENZA PANDEMIC	80
<i>TABLE 27 ESTIMATED NUMBER OF INPATIENT CARE FACILITIES AND AVAILABLE BEDS BY SELECTED COUNTRY, 2013 ESTIMATES</i>	80
<i>FIGURE 9 ESTIMATED NUMBER OF AVAILABLE BEDS BY SELECTED COUNTRY, 2013 ESTIMATES (NUMBER)</i>	81
ANTIVIRAL RESISTANCE	81
CHAPTER 5 PATENT ANALYSIS	84
OVERVIEW	84
INFLUENZA PATENTS BY PATENT NUMBER	84
<i>TABLE 28 PATENTS FOR INFLUENZA BY YEAR ISSUED, 2002-2012 (NO. OF PATENTS)</i>	84
<i>FIGURE 10 PATENTS FOR INFLUENZA BY YEAR ISSUED, 2002-2012 (NO. OF PATENTS)</i>	84
<i>TABLE 29 RECENT U.S. PATENTS FOR INFLUENZA TECHNOLOGY BY PATENT NUMBER</i>	85
<i>TABLE 30 NUMBER OF U.S. PATENTS FOR INFLUENZA MARKET COMPETITOR</i>	89
BRISTOL-MYERS SQUIBB	90
CRUCELL HOLLAND	90
MEDIMMUNE	91
NEW YORK UNIVERSITY	91
NOVARTIS	92
NOVAVAX	92
UNIVERSITY OF PITTSBURGH	92
WISCONSIN ALUMNI RESEARCH FOUNDATION	93
YEDA RESEARCH AND DEVELOPMENT	93
CHAPTER 6 INFLUENZA VACCINES	95
OVERVIEW	95
HISTORY OF VACCINE MANUFACTURER PARTICIPATION IN THE U.S.	95
<i>TABLE 31 VACCINE MANUFACTURER PARTICIPATION IN THE U.S., 2004-2014 INFLUENZA YEAR</i>	95
CURRENT VACCINES	97
BAXTER INTERNATIONAL	97
CSL BIOTHERAPIES	97
GLAXOSMITHKLINE	97
MEDIMMUNE	98
NOVARTIS	98
PROTEIN SCIENCES CORP.	99
SANOFI PASTEUR	99
SOLVAY PHARMACEUTICALS	99
<i>TABLE 32 EXAMPLES OF MARKETED INFLUENZA VACCINE PRODUCTS</i>	100
SEASONAL 2008-2009 VACCINE APPROVALS BY FDA	100
<i>TABLE 33 SEASONAL INFLUENZA VACCINE FDA APPROVALS FOR THE 2013-2014 INFLUENZA SEASON, BASED ON ADULT DOSAGE</i>	101
RECENT PRE-PANDEMIC AND PANDEMIC APPROVALS	101
VACCINE DEVELOPMENTS	101
ALPHAVAX	101
ANTIGEN EXPRESS	101
BIONDVAX PHARMACEUTICALS	102

TOPIC	PAGE NO.
CRUCELL	102
CURELAB	102
GENEREX BIOTECHNOLOGY	102
IBIO, INC.	102
INOVIO PHARMACEUTICALS	102
MEDICAGO	103
MEDIMMUNE	103
NANOBIO CORP.	103
NANOTHERAPEUTICS, INC.	103
NANOVIRICIDES, INC.	104
NEXBIO, INC.	104
NOVARTIS VACCINES	104
NOVAVAX, INC.	104
PAXVAX CORP.	105
PROTEIN SCIENCES CORP.	105
SANOFI PASTEUR	105
VAXART, INC.	105
VAXIN, INC.	105
VAXINNATE	106
<i>TABLE 34 RESEARCH AND DEVELOPMENT EFFORTS BY PROGRESS</i>	106
<i>FIGURE 11 NUMBER OF INFLUENZA RESEARCH AND DEVELOPMENT PROJECTS BY PROGRESS</i>	108
RECENT INDUSTRY NEWS	109
THE GLOBAL INFLUENZA VACCINE MARKET	109
<i>TABLE 35 GLOBAL REVENUES FOR INFLUENZA VACCINES BY MANUFACTURER, THROUGH 2018 (\$ MILLIONS)</i>	110
<i>FIGURE 12 GLOBAL REVENUES FOR INFLUENZA VACCINES BY MANUFACTURER, 2010-2018 (\$ MILLIONS)</i>	110
SEASONAL VS. PANDEMIC SALES	111
<i>FIGURE 13 GLOBAL REVENUES FOR INFLUENZA VACCINES BY SEASONAL VS. PANDEMIC SUPPLY ORDERS, 2007-2013 (\$ MILLIONS)</i>	111
REGIONAL MARKET SUMMARY	111
<i>TABLE 36 GLOBAL REVENUES FOR INFLUENZA VACCINES BY REGION, 2007-2018 (\$ MILLIONS)</i>	112
<i>FIGURE 14 GLOBAL REVENUES FOR INFLUENZA VACCINES BY REGION, 2007-2018 (\$ MILLIONS)</i>	112
<i>FIGURE 15 DISTRIBUTION OF GLOBAL INFLUENZA VACCINE SALES BY REGION, 2013 (%)</i>	112
THE U.S. INFLUENZA VACCINE MARKET	113
<i>TABLE 37 U.S. REVENUES FOR INFLUENZA VACCINES BY MANUFACTURER, 2007-2018 (\$ MILLIONS)</i>	114
<i>FIGURE 16 U.S. REVENUES FOR INFLUENZA VACCINES BY MANUFACTURER, 2010-2018 (\$ MILLIONS)</i>	115
<i>TABLE 38 ESTIMATED TOTAL UNITS SHIPPED TO THE U.S. BY INFLUENZA SEASON, 2005-2013</i>	115
<i>FIGURE 17 ESTIMATED TOTAL UNITS SHIPPED TO THE U.S. BY SEASON, 2005-2013</i>	115
<i>TABLE 39 UNITS FOR INFLUENZA VACCINES DISTRIBUTED IN THE U.S. BY MANUFACTURER, 2012-2013 SEASON (UNITS PER MILLION)</i>	116
<i>FIGURE 18 SHARE OF UNITS FOR INFLUENZA VACCINES DISTRIBUTED IN THE U.S. BY MANUFACTURER, 2012-2013 SEASON (%)</i>	116

TOPIC	PAGE NO.
THE EUROPEAN INFLUENZA VACCINE MARKET	116
<i>TABLE 40 EUROPE REVENUES FOR INFLUENZA VACCINES BY MANUFACTURER, THROUGH 2018 (\$ MILLIONS)</i>	117
<i>FIGURE 19 EUROPE REVENUES FOR INFLUENZA VACCINES BY MANUFACTURER, 2010-2018 (\$ MILLIONS)</i>	117
COMPETITOR ANALYSIS	118
<i>TABLE 41 LEADING PARTICIPANTS' SHARE OF INFLUENZA VACCINES BASED ON GLOBAL REVENUES, 2010-2013 (%)</i>	118
<i>FIGURE 20 LEADING PARTICIPANTS' SHARE OF INFLUENZA VACCINES BASED ON GLOBAL REVENUES, 2010 (%)</i>	119
<i>FIGURE 21 LEADING PARTICIPANTS' SHARE OF INFLUENZA BASED ON GLOBAL REVENUES, 2011 (%)</i>	119
<i>FIGURE 22 LEADING PARTICIPANTS' SHARE OF INFLUENZA VACCINES BASED ON GLOBAL REVENUES, 2012 (%)</i>	119
<i>FIGURE 23 LEADING PARTICIPANTS' SHARE OF INFLUENZA VACCINES BASED ON GLOBAL REVENUES, 2013 (%)</i>	120
CHAPTER 7 INFLUENZA THERAPIES	122
OVERVIEW	122
CURRENT THERAPIES	122
GLAXOSMITHKLINE	122
ROCHE	122
OTHERS	122
<i>TABLE 42 MARKETED THERAPIES, THROUGH 2013</i>	123
SEASONAL DOSAGE RECOMMENDATIONS FOR ANTIVIRALS	123
<i>TABLE 43 RECOMMENDED DAILY DOSAGE OF SEASONAL INFLUENZA ANTIVIRAL MEDICATIONS BY ANTIVIRAL AGENT AND AGE: U.S.</i>	123
GENERIC AVAILABILITY	125
<i>TABLE 44 GENERIC FDA APPROVALS OF INFLUENZA APPROVED TREATMENTS</i>	126
INFLUENZA BIOLOGICAL DEVELOPMENTS	126
ADAMAS PHARMACEUTICALS	126
AMARILLO BIOSCIENCES, INC.	127
BIOCRIST PHARMACEUTICALS	127
BIOTA HOLDINGS	127
CRUCCELL	127
FUNCTIONAL GENETICS, INC.	127
GLAXOSMITHKLINE	128
HEMISPHERX BIOPHARMA	128
ROMARK LABORATORIES	128
SAREPTA THERAPEUTICS	128
THERACLONE SCIENCES	128
TOYAMA CHEMICAL	129
<i>TABLE 45 RESEARCH AND DEVELOPMENT EFFORTS BY PROGRESS</i>	129
THE GLOBAL INFLUENZA THERAPEUTICS MARKET	130
<i>TABLE 46 GLOBAL REVENUES FOR INFLUENZA THERAPEUTICS BY MANUFACTURER, THROUGH 2018 (\$ MILLIONS)</i>	131
<i>FIGURE 24 GLOBAL REVENUES FOR INFLUENZA THERAPEUTICS BY MANUFACTURER, 2010-2018 (\$ MILLIONS)</i>	131
REGIONAL MARKET SUMMARY	131

TOPIC	PAGE NO.
<i>TABLE 47 GLOBAL REVENUES FOR INFLUENZA THERAPEUTICS BY REGION, THROUGH 2018 (\$ MILLIONS)</i>	132
<i>FIGURE 25 GLOBAL REVENUES FOR INFLUENZA THERAPEUTICS BY REGION, 2010-2018 (\$ MILLIONS)</i>	132
<i>FIGURE 26 DISTRIBUTION OF GLOBAL INFLUENZA THERAPEUTICS SALES BY REGION, 2013 (%)</i>	132
Influenza Therapeutics Market in The U.S.	133
<i>TABLE 48 U.S. REVENUES FOR INFLUENZA THERAPEUTICS BY MANUFACTURER, THROUGH 2018 (\$ MILLIONS)</i>	134
<i>FIGURE 27 U.S. REVENUES FOR INFLUENZA THERAPEUTICS BY MANUFACTURER, 2010-2018 (\$ MILLIONS)</i>	134
Influenza Therapeutics Market In Europe	134
<i>TABLE 49 EUROPE REVENUES FOR INFLUENZA THERAPEUTICS BY MANUFACTURER, THROUGH 2018 (\$ MILLIONS)</i>	135
<i>FIGURE 28 EUROPE REVENUES FOR INFLUENZA THERAPEUTICS BY MANUFACTURER, 2010-2018 (\$ MILLIONS)</i>	135
COMPETITOR ANALYSIS	135
<i>TABLE 50 LEADING PARTICIPANTS FOR INFLUENZA THERAPEUTICS BASED ON GLOBAL REVENUES, 2010-2013 (%)</i>	136
<i>FIGURE 29 LEADING PARTICIPANTS FOR INFLUENZA THERAPEUTICS BASED ON GLOBAL REVENUES, 2010 (%)</i>	136
<i>FIGURE 30 LEADING PARTICIPANTS FOR INFLUENZA BASED ON GLOBAL REVENUES, 2011 (%)</i>	137
<i>FIGURE 31 LEADING PARTICIPANTS FOR INFLUENZA BASED ON GLOBAL REVENUES, 2012 (%)</i>	137
<i>FIGURE 32 LEADING PARTICIPANTS FOR INFLUENZA BASED ON GLOBAL REVENUES, 2013 (%)</i>	137
CHAPTER 8 INFLUENZA VACCINE/THERAPEUTICS MARKET ANALYSIS	140
<i>TABLE 51 REVENUES FOR INFLUENZA THERAPEUTICS AND VACCINES BY REGION, THROUGH 2018 (\$ MILLIONS)</i>	140
<i>FIGURE 33 REVENUES FOR INFLUENZA THERAPEUTICS AND VACCINES BY REGION, 2010-2018 (\$ MILLIONS)</i>	141
<i>FIGURE 34 DISTRIBUTION OF GLOBAL INFLUENZA THERAPEUTICS AND VACCINES SALES BY REGION, 2013 (%)</i>	141
<i>TABLE 52 REVENUES FOR INFLUENZA THERAPEUTICS AND VACCINES BY PRODUCT TYPE, THROUGH 2018 (\$ MILLIONS)</i>	142
<i>FIGURE 35 REVENUES FOR INFLUENZA THERAPEUTICS AND VACCINES BY PRODUCT TYPE, 2010-2018 (\$ MILLIONS)</i>	143
<i>FIGURE 36 DISTRIBUTION OF GLOBAL INFLUENZA THERAPEUTICS AND VACCINES BY PRODUCT TYPE, 2013 (%)</i>	143
CLINICAL TRIALS	144
<i>TABLE 53 CLINICAL TRIALS FOR INFLUENZA VACCINES AND THERAPEUTICS BY SELECTED COUNTRY AND TRIAL STATUS</i>	144
<i>FIGURE 37 CLINICAL TRIALS FOR INFLUENZA VACCINES AND THERAPEUTICS BY SELECTED COUNTRY AND TRIAL STATUS</i>	144
CHAPTER 9 INFLUENZA DIAGNOSTICS	147
OVERVIEW	147
<i>TABLE 54 INFLUENZA DIAGNOSTIC TABLE</i>	147
TEST DESCRIPTIONS2	148

TOPIC	PAGE NO.
Viral Culture	148
Rapid Influenza Diagnostic Tests	148
<i>TABLE 55 CLINICAL CONSIDERATIONS OF RAPID TESTING WHEN INFLUENZA PREVALENCE IS HIGH (%)</i>	149
<i>TABLE 56 CLINICAL CONSIDERATIONS OF RAPID TESTING WHEN INFLUENZA PREVALENCE IS LOW (%)</i>	149
Serologic Testing	150
PRODUCT DESCRIPTION	150
Conventional Laboratory Tests	150
Applied Biosystems	150
Qiagen, Inc.	150
Rapid Testing	150
3M and Response Biomedical Corp.	151
Alere	151
Becton Dickinson	151
BTNX, Inc.	152
Cepheid	152
Hologic, Inc.	152
Luminex Corp.	153
Meridian Biosciences, Inc.	153
OraSure Technologies	153
Quidel Corp.	153
Remel, Inc. (Thermo Scientific)	154
SA Scientific, Ltd.	154
Sekisui Diagnostics	154
<i>TABLE 57 SELECTED MARKETED RAPID TEST PRODUCTS, THROUGH AUGUST 2013</i>	154
<i>TABLE 58 SELECTED RAPID INFLUENZA TESTS AVERAGE PRICE (\$)</i>	156
LABORATORY SERVICES	156
Associated Regional University Pathologists (ARUP) Laboratories	156
Bio-Reference Laboratories, Inc.	156
Laboratory Corp. of America	156
Pathology Associates Medical Laboratories	157
Quest Diagnostics	157
<i>TABLE 59 PROVIDERS OF TEST SERVICES</i>	157
RECENT INDUSTRY NEWS	157
MARKET ANALYSIS	158
<i>TABLE 60 REVENUES FOR INFLUENZA DIAGNOSTICS BY PRODUCT TYPE, THROUGH 2018 (\$ MILLIONS)</i>	158
<i>FIGURE 38 REVENUES FOR INFLUENZA DIAGNOSTICS BY PRODUCT TYPE, 2010-2018 (\$ MILLIONS)</i>	158
REGIONAL MARKET SUMMARY	159
<i>TABLE 61 GLOBAL REVENUES FOR INFLUENZA DIAGNOSTICS BY REGION, THROUGH 2018 (\$ MILLIONS)</i>	159
<i>FIGURE 39 GLOBAL REVENUES FOR INFLUENZA DIAGNOSTICS BY REGION, 2010-2018 (\$ MILLIONS)</i>	159
<i>FIGURE 40 DISTRIBUTION OF GLOBAL INFLUENZA DIAGNOSTICS SALES, BY REGION, 2013 (%)</i>	160
<i>TABLE 62 NUMBER OF CLIA-WAIVED TESTS APPROVED BY YEAR FOR INFLUENZA INDICATIONS IN THE U.S., 2000-2013*</i>	161

TOPIC	PAGE NO.
<i>FIGURE 41 NUMBER OF CLIA-WAIVED TESTS APPROVED BY YEAR FOR INFLUENZA INDICATIONS IN THE U.S., 2000-2013*</i>	161
COMPETITOR ANALYSIS	161
<i>TABLE 63 LEADING PARTICIPANTS FOR INFLUENZA DIAGNOSTICS BY PERCENTAGE, BASED ON GLOBAL REVENUES, 2010-2013 (\$)</i>	162
<i>FIGURE 42 LEADING PARTICIPANTS FOR INFLUENZA DIAGNOSTICS BY PERCENTAGE, BASED ON GLOBAL REVENUES, 2010 (%)</i>	162
<i>FIGURE 43 LEADING PARTICIPANTS FOR INFLUENZA DIAGNOSTICS BY PERCENTAGE, BASED ON GLOBAL REVENUES, 2011 (%)</i>	162
<i>FIGURE 44 LEADING PARTICIPANTS FOR INFLUENZA DIAGNOSTICS BY PERCENTAGE, BASED ON GLOBAL REVENUES, 2012 (%)</i>	163
<i>FIGURE 45 LEADING PARTICIPANTS FOR INFLUENZA DIAGNOSTICS BY PERCENTAGE, BASED ON GLOBAL REVENUES, 2013 (%)</i>	163
CHAPTER 10 INFLUENZA MARKET SUMMARY	166
TOTAL MARKET ANALYSIS	166
<i>TABLE 64 GLOBAL INFLUENZA MARKET ANALYSIS BY REVENUE SEGMENT, THROUGH 2018 (\$ MILLIONS)</i>	166
<i>FIGURE 46 GLOBAL INFLUENZA MARKET ANALYSIS BY REVENUE SEGMENT, 2010-2018 (\$ MILLIONS)</i>	166
<i>FIGURE 47 DISTRIBUTION OF GLOBAL INFLUENZA MARKET, BY REVENUE SEGMENT, 2013 (%)</i>	167
REGIONAL MARKET SUMMARY	168
<i>TABLE 65 GLOBAL INFLUENZA MARKET BY REGION, THROUGH 2018 (\$ MILLIONS)</i>	168
<i>FIGURE 48 GLOBAL INFLUENZA MARKET BY REGION, 2010-2018 (\$ MILLIONS)</i>	169
<i>FIGURE 49 DISTRIBUTION OF GLOBAL INFLUENZA MARKET BY REGION, 2013 (%)</i>	169
OVERVIEW OF INFLUENZA MARKET TRENDS	170
<i>TABLE 66 INFLUENZA VACCINE MARKET DRIVERS AND RESISTORS</i>	170
<i>TABLE 67 INFLUENZA THERAPEUTIC MARKET DRIVERS AND RESISTORS</i>	170
<i>TABLE 68 INFLUENZA DIAGNOSTIC MARKET DRIVERS AND RESISTORS</i>	170
INDUSTRY PARTICIPANTS	171
<i>TABLE 69 MAJOR INDUSTRY PARTICIPANTS BY PRODUCT SEGMENT, INDUSTRY PARTICIPANTS BY TYPE</i>	171
CHAPTER 11 COMPANY PROFILES	173
SIGNIFICANT COMPANY ACQUISITIONS	173
ABBOTT LABORATORIES	173
<i>TABLE 70 ABBOTT'S COMPANY REVENUES, 2009-2012 (\$ MILLIONS)</i>	174
<i>FIGURE 50 ABBOTT'S COMPANY REVENUES, 2009-2012 (\$ MILLIONS)</i>	174
ALERE INC.	174
<i>TABLE 71 ALERE'S COMPANY REVENUES, 2009-2012 (\$ MILLIONS)</i>	175
<i>FIGURE 51 ALERE'S COMPANY REVENUES, 2009-2012 (\$ MILLIONS)</i>	175
ASTRAZENECA/MEDIMMUNE	175
<i>TABLE 72 ASTRAZENECA'S COMPANY REVENUES, 2009-2012 (\$ MILLIONS)</i>	176
<i>FIGURE 52 ASTRAZENECA'S COMPANY REVENUES, 2009-2012 (\$ MILLIONS)</i>	176
BECTON DICKINSON AND COMPANY	177
<i>TABLE 73 BECTON DICKINSON'S COMPANY REVENUES, 2009-2012 (\$ MILLIONS)</i>	178
<i>FIGURE 53 BECTON DICKINSON'S COMPANY REVENUES, 2009-2012 (\$ MILLIONS)</i>	178
CSL LIMITED	178

TOPIC	PAGE NO.
<i>TABLE 74 CSL LIMITED'S COMPANY REVENUES, 2009-2013* (\$ MILLIONS)</i>	179
<i>FIGURE 54 CSL LIMITED'S COMPANY REVENUES, 2009-2013* (\$ MILLIONS)</i>	179
GLAXOSMITHKLINE PLC	180
<i>TABLE 75 GLAXOSMITHKLINE'S COMPANY REVENUES, 2009-2012 (\$ MILLIONS)</i>	180
<i>FIGURE 55 GLAXOSMITHKLINE'S COMPANY REVENUES 2009-2012 (\$ MILLIONS)</i>	181
MITSUBISHI TANABE PHARMA CORP.	181
<i>TABLE 76 MITSUBISHI TANABE'S COMPANY REVENUES, 2009-2012 (\$ MILLIONS)</i>	182
<i>FIGURE 56 MITSUBISHI TANABE'S COMPANY REVENUES, 2009-2012 (\$ MILLIONS)</i>	182
NOVARTIS AG	182
<i>TABLE 77 NOVARTIS' COMPANY REVENUES, 2009-2012 (\$ MILLIONS)</i>	183
<i>FIGURE 57 NOVARTIS' COMPANY REVENUES, 2009-2012 (\$ MILLIONS)</i>	183
QUIDEL CORP.	183
<i>TABLE 78 QUIDEL'S COMPANY REVENUES, 2009-2012 (\$ MILLIONS)</i>	184
<i>FIGURE 58 QUIDEL'S COMPANY REVENUES, 2009-2012 (\$ MILLIONS)</i>	184
ROCHE LTD.	185
<i>TABLE 79 ROCHE GROUP'S REVENUES, 2009-2012 (\$ MILLIONS)</i>	185
<i>FIGURE 59 ROCHE GROUP'S REVENUES, 2009-2012 (\$ MILLIONS)</i>	185
SANOFI/SANOFI PASTEUR	186
<i>TABLE 80 SANOFI'S COMPANY REVENUES, 2009-2012 (\$ MILLIONS)</i>	187
<i>FIGURE 60 SANOFI'S COMPANY REVENUES, 2009-2012 (\$ MILLIONS)</i>	188
CHAPTER 12 APPENDICES	190
APPENDIX I	190
MANUFACTURERS AND DEVELOPERS	190
APPENDIX II	202
MENTIONED UNIVERSITIES AND SCHOOLS	202
APPENDIX III	204
GLOSSARY OF TERMS3	204
APPENDIX IV	206
LIST OF ACRONYMS	206

LIST OF TABLES

TABLE HEADING	PAGE NO.
SUMMARY TABLE GLOBAL INFLUENZA MARKET ANALYSIS BY PRODUCT SEGMENT, THROUGH 2018 (\$ MILLIONS)	7
TABLE 1 DISTRIBUTION OF FATAL CASES OF 2009-2010 H1N1 PANDEMIC BY WHO REGION	11
TABLE 2 CUMULATIVE NUMBER OF CONFIRMED CASES AND DEATHS OF H7N9 BY MONTH, AS OF AUGUST 2013	12
TABLE 3 NUMBER OF CONFIRMED CASES OF H7N9 BY REGION, AS OF AUGUST 2013	12
TABLE 4 WORLDWIDE INFLUENZA ACTIVITY, COUNTRIES AFFECTED BY TYPE	15
TABLE 5 VIRAL SURVEILLANCE, PERCENT OF INFLUENZA VIRUS TYPE, 2005-2011 FLU SEASONS (%)	19
TABLE 6 INFLUENZA VIRUS RECOMMENDATIONS, U.S. INFLUENZA SEASONS, 2003-2014	20
TABLE 7 THIMEROSAL CONTENT OF INFLUENZA VACCINES (U.S. MANUFACTURED)	22
TABLE 8 CDC INFLUENZA VACCINE RECOMMENDATIONS	23
TABLE 9 GLOBAL POPULATION AND ANNUAL GROWTH BY SELECTED AGE GROUP AND SELECTED YEARS, THROUGH 2030 (MILLIONS)	26
TABLE 10 GLOBAL POPULATION BY SELECTED COUNTRY, THROUGH 2015 (MILLIONS)	27
TABLE 11 GLOBAL LIFE EXPECTANCY AT BIRTH BY SELECTED COUNTRY, 1980 AND 2010 (YEARS)	29
TABLE 12 WORLDWIDE INFLUENZA STATISTICS, ESTIMATED ON 2012 DATA AND POPULATION	30
TABLE 13 U.S. VIRAL STATISTICS ESTIMATED ON 2012 DATA AND POPULATION	30
TABLE 14 IMPACT OF 2009 H1N1 FLU, CASES AND RELATED HOSPITALIZATIONS AND DEATHS BY AGE GROUP APRIL 2009-APRIL 2010	31
TABLE 15 COUNTRIES/REGIONS AFFECTED BY CURRENT CDC AND USDA BIRD IMPORT RESTRICTIONS	36
TABLE 16 WHO-REPORTED CASES OF AVIAN INFLUENZA A/(H5N1) IN HUMANS (NUMBER)	37
TABLE 17 CONFIRMED CASES OF AVIAN FLU OUTBREAKS IN ANIMALS WORLDWIDE, 2003 TO AUGUST 19, 2013 (NUMBER)	39
TABLE 18 APPROVED WHO INFLUENZA CENTERS BY REGION	42
TABLE 19 TARGETED PRE-PANDEMIC INFLUENZA VACCINE STOCKPILES, BASED ON POPULATION DEMANDS OF SELECTED COUNTRIES (MILLIONS)	64
TABLE 20 HHS CONTRACTS AWARDED FOR RESEARCH AND DEVELOPMENT OF RECOMBINANT INFLUENZA VACCINE	67
TABLE 21 ESTIMATED INCIDENCE OF PANDEMIC INFLUENZA FOR 2013 SEVERE OUTBREAKS BASED ON POPULATION ESTIMATES, U.S. CENSUS BUREAU INTERNATIONAL DATABASE SELECTED COUNTRIES (THOUSANDS)	69
TABLE 22 ESSENTIAL AND DESIRABLE ELEMENTS OF THE WHO INFLUENZA PANDEMIC PREPAREDNESS PLAN	71
TABLE 23 OUTLINE OF JAPAN'S GOVERNMENT ACTION PLAN FOR INFLUENZA PANDEMIC PREPAREDNESS	74
TABLE 24 CHINA INFLUENZA PANDEMIC WARNING LEVELS	76
TABLE 25 BRAZIL INFLUENZA PANDEMIC WARNING LEVELS AND ACTION	76
TABLE 26 NATIONWIDE INFLUENZA-RELATED COSTS AND DISTRIBUTIONS BY AGE GROUP, BY RISK AND BY HEALTH OUTCOME, ALL ADOPTED FROM MOLINARI ET AL., 2007	78
TABLE 27 ESTIMATED NUMBER OF INPATIENT CARE FACILITIES AND AVAILABLE BEDS BY SELECTED COUNTRY, 2013 ESTIMATES	80
TABLE 28 PATENTS FOR INFLUENZA BY YEAR ISSUED, 2002-2012 (NO. OF PATENTS)	84

TABLE HEADING	PAGE NO.
TABLE 29 RECENT U.S. PATENTS FOR INFLUENZA TECHNOLOGY BY PATENT NUMBER	85
TABLE 30 NUMBER OF U.S. PATENTS FOR INFLUENZA MARKET COMPETITOR	89
TABLE 31 VACCINE MANUFACTURER PARTICIPATION IN THE U.S., 2004-2014 INFLUENZA YEAR	95
TABLE 32 EXAMPLES OF MARKETED INFLUENZA VACCINE PRODUCTS	100
TABLE 33 SEASONAL INFLUENZA VACCINE FDA APPROVALS FOR THE 2013-2014 INFLUENZA SEASON, BASED ON ADULT DOSAGE	101
TABLE 34 RESEARCH AND DEVELOPMENT EFFORTS BY PROGRESS	106
TABLE 35 GLOBAL REVENUES FOR INFLUENZA VACCINES BY MANUFACTURER, THROUGH 2018 (\$ MILLIONS)	110
TABLE 36 GLOBAL REVENUES FOR INFLUENZA VACCINES BY REGION, 2007-2018 (\$ MILLIONS)	112
TABLE 37 U.S. REVENUES FOR INFLUENZA VACCINES BY MANUFACTURER, 2007-2018 (\$ MILLIONS)	114
TABLE 38 ESTIMATED TOTAL UNITS SHIPPED TO THE U.S. BY INFLUENZA SEASON, 2005-2013	115
TABLE 39 UNITS FOR INFLUENZA VACCINES DISTRIBUTED IN THE U.S. BY MANUFACTURER, 2012-2013 SEASON (UNITS PER MILLION)	116
TABLE 40 EUROPE REVENUES FOR INFLUENZA VACCINES BY MANUFACTURER, THROUGH 2018 (\$ MILLIONS)	117
TABLE 41 LEADING PARTICIPANTS' SHARE OF INFLUENZA VACCINES BASED ON GLOBAL REVENUES, 2010-2013 (%)	118
TABLE 42 MARKETED THERAPIES, THROUGH 2013	123
TABLE 43 RECOMMENDED DAILY DOSAGE OF SEASONAL INFLUENZA ANTIVIRAL MEDICATIONS BY ANTIVIRAL AGENT AND AGE: U.S.	123
TABLE 44 GENERIC FDA APPROVALS OF INFLUENZA APPROVED TREATMENTS	126
TABLE 45 RESEARCH AND DEVELOPMENT EFFORTS BY PROGRESS	129
TABLE 46 GLOBAL REVENUES FOR INFLUENZA THERAPEUTICS BY MANUFACTURER, THROUGH 2018 (\$ MILLIONS)	131
TABLE 47 GLOBAL REVENUES FOR INFLUENZA THERAPEUTICS BY REGION, THROUGH 2018 (\$ MILLIONS)	132
TABLE 48 U.S. REVENUES FOR INFLUENZA THERAPEUTICS BY MANUFACTURER, THROUGH 2018 (\$ MILLIONS)	134
TABLE 49 EUROPE REVENUES FOR INFLUENZA THERAPEUTICS BY MANUFACTURER, THROUGH 2018 (\$ MILLIONS)	135
TABLE 50 LEADING PARTICIPANTS FOR INFLUENZA THERAPEUTICS BASED ON GLOBAL REVENUES, 2010-2013 (%)	136
TABLE 51 REVENUES FOR INFLUENZA THERAPEUTICS AND VACCINES BY REGION, THROUGH 2018 (\$ MILLIONS)	140
TABLE 52 REVENUES FOR INFLUENZA THERAPEUTICS AND VACCINES BY PRODUCT TYPE, THROUGH 2018 (\$ MILLIONS)	142
TABLE 53 CLINICAL TRIALS FOR INFLUENZA VACCINES AND THERAPEUTICS BY SELECTED COUNTRY AND TRIAL STATUS	144
TABLE 54 INFLUENZA DIAGNOSTIC TABLE	147
TABLE 55 CLINICAL CONSIDERATIONS OF RAPID TESTING WHEN INFLUENZA PREVALENCE IS HIGH (%)	149
TABLE 56 CLINICAL CONSIDERATIONS OF RAPID TESTING WHEN INFLUENZA PREVALENCE IS LOW (%)	149
TABLE 57 SELECTED MARKETED RAPID TEST PRODUCTS, THROUGH AUGUST 2013	154
TABLE 58 SELECTED RAPID INFLUENZA TESTS AVERAGE PRICE (\$)	156
TABLE 59 PROVIDERS OF TEST SERVICES	157

TABLE HEADING	PAGE NO.
TABLE 60 REVENUES FOR INFLUENZA DIAGNOSTICS BY PRODUCT TYPE, THROUGH 2018 (\$ MILLIONS)	158
TABLE 61 GLOBAL REVENUES FOR INFLUENZA DIAGNOSTICS BY REGION, THROUGH 2018 (\$ MILLIONS)	159
TABLE 62 NUMBER OF CLIA-WAIVED TESTS APPROVED BY YEAR FOR INFLUENZA INDICATIONS IN THE U.S., 2000-2013*	161
TABLE 63 LEADING PARTICIPANTS FOR INFLUENZA DIAGNOSTICS BY PERCENTAGE, BASED ON GLOBAL REVENUES, 2010-2013 (\$)	162
TABLE 64 GLOBAL INFLUENZA MARKET ANALYSIS BY REVENUE SEGMENT, THROUGH 2018 (\$ MILLIONS)	166
TABLE 65 GLOBAL INFLUENZA MARKET BY REGION, THROUGH 2018 (\$ MILLIONS)	168
TABLE 66 INFLUENZA VACCINE MARKET DRIVERS AND RESISTORS	170
TABLE 67 INFLUENZA THERAPEUTIC MARKET DRIVERS AND RESISTORS	170
TABLE 68 INFLUENZA DIAGNOSTIC MARKET DRIVERS AND RESISTORS	170
TABLE 69 MAJOR INDUSTRY PARTICIPANTS BY PRODUCT SEGMENT, INDUSTRY PARTICIPANTS BY TYPE	171
TABLE 70 ABBOTT'S COMPANY REVENUES, 2009-2012 (\$ MILLIONS)	174
TABLE 71 ALERE'S COMPANY REVENUES, 2009-2012 (\$ MILLIONS)	175
TABLE 72 ASTRAZENECA'S COMPANY REVENUES, 2009-2012 (\$ MILLIONS)	176
TABLE 73 BECTON DICKINSON'S COMPANY REVENUES, 2009-2012 (\$ MILLIONS)	178
TABLE 74 CSL LIMITED'S COMPANY REVENUES, 2009-2013* (\$ MILLIONS)	179
TABLE 75 GLAXOSMITHKLINE'S COMPANY REVENUES, 2009-2012 (\$ MILLIONS)	180
TABLE 76 MITSUBISHI TANABE'S COMPANY REVENUES, 2009-2012 (\$ MILLIONS)	182
TABLE 77 NOVARTIS' COMPANY REVENUES, 2009-2012 (\$ MILLIONS)	183
TABLE 78 QUIDEL'S COMPANY REVENUES, 2009-2012 (\$ MILLIONS)	184
TABLE 79 ROCHE GROUP'S REVENUES, 2009-2012 (\$ MILLIONS)	185
TABLE 80 SANOFI'S COMPANY REVENUES, 2009-2012 (\$ MILLIONS)	187

LIST OF FIGURES

FIGURE TITLE	PAGE NO.
SUMMARY FIGURE GLOBAL INFLUENZA MARKET ANALYSIS BY PRODUCT SEGMENT, 2007-2018 (\$ MILLIONS)	7
FIGURE 1 VIRAL SURVEILLANCE TREND FOR INFLUENZA VIRUS TYPE, 2005-2011 FLU SEASONS (%)	19
FIGURE 2 RECOMMENDATIONS REGARDING INFLUENZA VACCINATION OF PERSONS WHO REPORT ALLERGY TO EGGS: ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES, U.S., 2013-2014 INFLUENZA SEASON	24
FIGURE 3 GLOBAL POPULATION BY SELECTED AGE GROUP AND SELECTED YEARS, 2000-2030 (MILLIONS)	26
FIGURE 4 GLOBAL POPULATION BY SELECTED COUNTRY, 2010 AND PROJECTED 2015 (MILLIONS)	28
FIGURE 5 GLOBAL LIFE EXPECTANCY AT BIRTH BY SELECTED COUNTRY, 1980 AND 2010 (YEARS)	29
FIGURE 6 WHO-REPORTED CASES OF AVIAN INFLUENZA A/(H5N1) IN HUMANS (NUMBER)	38
FIGURE 7 CONFIRMED CASES OF AVIAN FLU OUTBREAKS IN ANIMALS WORLDWIDE, BY REGION, 2003 TO AUGUST 19, 2013 (NUMBER)	40
FIGURE 8 NUMBER OF APPROVED WHO INFLUENZA CENTERS BY WHO BROAD REGION (%)	62
FIGURE 9 ESTIMATED NUMBER OF AVAILABLE BEDS BY SELECTED COUNTRY, 2013 ESTIMATES (NUMBER)	81
FIGURE 10 PATENTS FOR INFLUENZA BY YEAR ISSUED, 2002-2012 (NO. OF PATENTS)	84
FIGURE 11 NUMBER OF INFLUENZA RESEARCH AND DEVELOPMENT PROJECTS BY PROGRESS	108
FIGURE 12 GLOBAL REVENUES FOR INFLUENZA VACCINES BY MANUFACTURER, 2010-2018 (\$ MILLIONS)	110
FIGURE 13 GLOBAL REVENUES FOR INFLUENZA VACCINES BY SEASONAL VS. PANDEMIC SUPPLY ORDERS, 2007-2013 (\$ MILLIONS)	111
FIGURE 14 GLOBAL REVENUES FOR INFLUENZA VACCINES BY REGION, 2007-2018 (\$ MILLIONS)	112
FIGURE 15 DISTRIBUTION OF GLOBAL INFLUENZA VACCINE SALES BY REGION, 2013 (%)	112
FIGURE 16 U.S. REVENUES FOR INFLUENZA VACCINES BY MANUFACTURER, 2010-2018 (\$ MILLIONS)	115
FIGURE 17 ESTIMATED TOTAL UNITS SHIPPED TO THE U.S. BY SEASON, 2005-2013	115
FIGURE 18 SHARE OF UNITS FOR INFLUENZA VACCINES DISTRIBUTED IN THE U.S. BY MANUFACTURER, 2012-2013 SEASON (%)	116
FIGURE 19 EUROPE REVENUES FOR INFLUENZA VACCINES BY MANUFACTURER, 2010-2018 (\$ MILLIONS)	117
FIGURE 20 LEADING PARTICIPANTS' SHARE OF INFLUENZA VACCINES BASED ON GLOBAL REVENUES, 2010 (%)	119
FIGURE 21 LEADING PARTICIPANTS' SHARE OF INFLUENZA BASED ON GLOBAL REVENUES, 2011 (%)	119
FIGURE 22 LEADING PARTICIPANTS' SHARE OF INFLUENZA VACCINES BASED ON GLOBAL REVENUES, 2012 (%)	119
FIGURE 23 LEADING PARTICIPANTS' SHARE OF INFLUENZA VACCINES BASED ON GLOBAL REVENUES, 2013 (%)	120
FIGURE 24 GLOBAL REVENUES FOR INFLUENZA THERAPEUTICS BY MANUFACTURER, 2010-2018 (\$ MILLIONS)	131
FIGURE 25 GLOBAL REVENUES FOR INFLUENZA THERAPEUTICS BY REGION, 2010-2018 (\$ MILLIONS)	132

FIGURE TITLE	PAGE NO.
FIGURE 26 DISTRIBUTION OF GLOBAL INFLUENZA THERAPEUTICS SALES BY REGION, 2013 (%)	132
FIGURE 27 U.S. REVENUES FOR INFLUENZA THERAPEUTICS BY MANUFACTURER, 2010-2018 (\$ MILLIONS)	134
FIGURE 28 EUROPE REVENUES FOR INFLUENZA THERAPEUTICS BY MANUFACTURER, 2010-2018 (\$ MILLIONS)	135
FIGURE 29 LEADING PARTICIPANTS FOR INFLUENZA THERAPEUTICS BASED ON GLOBAL REVENUES, 2010 (%)	136
FIGURE 30 LEADING PARTICIPANTS FOR INFLUENZA BASED ON GLOBAL REVENUES, 2011 (%)	137
FIGURE 31 LEADING PARTICIPANTS FOR INFLUENZA BASED ON GLOBAL REVENUES, 2012 (%)	137
FIGURE 32 LEADING PARTICIPANTS FOR INFLUENZA BASED ON GLOBAL REVENUES, 2013 (%)	137
FIGURE 33 REVENUES FOR INFLUENZA THERAPEUTICS AND VACCINES BY REGION, 2010-2018 (\$ MILLIONS)	141
FIGURE 34 DISTRIBUTION OF GLOBAL INFLUENZA THERAPEUTICS AND VACCINES SALES BY REGION, 2013 (%)	141
FIGURE 35 REVENUES FOR INFLUENZA THERAPEUTICS AND VACCINES BY PRODUCT TYPE, 2010-2018 (\$ MILLIONS)	143
FIGURE 36 DISTRIBUTION OF GLOBAL INFLUENZA THERAPEUTICS AND VACCINES BY PRODUCT TYPE, 2013 (%)	143
FIGURE 37 CLINICAL TRIALS FOR INFLUENZA VACCINES AND THERAPEUTICS BY SELECTED COUNTRY AND TRIAL STATUS	144
FIGURE 38 REVENUES FOR INFLUENZA DIAGNOSTICS BY PRODUCT TYPE, 2010-2018 (\$ MILLIONS)	158
FIGURE 39 GLOBAL REVENUES FOR INFLUENZA DIAGNOSTICS BY REGION, 2010-2018 (\$ MILLIONS)	159
FIGURE 40 DISTRIBUTION OF GLOBAL INFLUENZA DIAGNOSTICS SALES, BY REGION, 2013 (%)	160
FIGURE 41 NUMBER OF CLIA-WAIVED TESTS APPROVED BY YEAR FOR INFLUENZA INDICATIONS IN THE U.S., 2000-2013*	161
FIGURE 42 LEADING PARTICIPANTS FOR INFLUENZA DIAGNOSTICS BY PERCENTAGE, BASED ON GLOBAL REVENUES, 2010 (%)	162
FIGURE 43 LEADING PARTICIPANTS FOR INFLUENZA DIAGNOSTICS BY PERCENTAGE, BASED ON GLOBAL REVENUES, 2011 (%)	162
FIGURE 44 LEADING PARTICIPANTS FOR INFLUENZA DIAGNOSTICS BY PERCENTAGE, BASED ON GLOBAL REVENUES, 2012 (%)	163
FIGURE 45 LEADING PARTICIPANTS FOR INFLUENZA DIAGNOSTICS BY PERCENTAGE, BASED ON GLOBAL REVENUES, 2013 (%)	163
FIGURE 46 GLOBAL INFLUENZA MARKET ANALYSIS BY REVENUE SEGMENT, 2010-2018 (\$ MILLIONS)	166
FIGURE 47 DISTRIBUTION OF GLOBAL INFLUENZA MARKET, BY REVENUE SEGMENT, 2013 (%)	167
FIGURE 48 GLOBAL INFLUENZA MARKET BY REGION, 2010-2018 (\$ MILLIONS)	169
FIGURE 49 DISTRIBUTION OF GLOBAL INFLUENZA MARKET BY REGION, 2013 (%)	169
FIGURE 50 ABBOTT'S COMPANY REVENUES, 2009-2012 (\$ MILLIONS)	174
FIGURE 51 ALERE'S COMPANY REVENUES, 2009-2012 (\$ MILLIONS)	175
FIGURE 52 ASTRAZENECA'S COMPANY REVENUES, 2009-2012 (\$ MILLIONS)	176
FIGURE 53 BECTON DICKINSON'S COMPANY REVENUES, 2009-2012 (\$ MILLIONS)	178
FIGURE 54 CSL LIMITED'S COMPANY REVENUES, 2009-2013* (\$ MILLIONS)	179
FIGURE 55 GLAXOSMITHKLINE'S COMPANY REVENUES 2009-2012 (\$ MILLIONS)	181

FIGURE TITLE	PAGE NO.
FIGURE 56 MITSUBISHI TANABE'S COMPANY REVENUES, 2009-2012 (\$ MILLIONS)	182
FIGURE 57 NOVARTIS' COMPANY REVENUES, 2009-2012 (\$ MILLIONS)	183
FIGURE 58 QUIDEL'S COMPANY REVENUES, 2009-2012 (\$ MILLIONS)	184
FIGURE 59 ROCHE GROUP'S REVENUES, 2009-2012 (\$ MILLIONS)	185
FIGURE 60 SANOFI'S COMPANY REVENUES, 2009-2012 (\$ MILLIONS)	188